Five Prime Thera (FPRX) Fundamental Analysis & Valuation
NASDAQ:FPRX
38
+0.01 (+0.03%)
At close: Apr 15, 2021
38
0 (0%)
After Hours: 4/15/2021, 8:00:00 PM
This FPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
No Fundamental Analysis report for FPRX not available.
FPRX Fundamentals: All Metrics, Ratios and Statistics
38
+0.01 (+0.03%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner Change0%
Market Cap1.77B
Revenue(TTM)13.18M
Net Income(TTM)-84.33M
Analysts75
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 134.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | -17.04 |
EPS(TTM)-2.29
EYN/A
EPS(NY)-2.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.28
BVpS5.69
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.43% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -704.74% | ||
| PM (TTM) | -639.92% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.18 | ||
| Quick Ratio | 13.18 | ||
| Altman-Z | 13.89 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.7%
EPS Next Y6.99%
EPS Next 2Y9.83%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.4%
Revenue growth 3YN/A
Revenue growth 5Y-48.94%
Sales Q2Q%-122.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
Five Prime Thera / FPRX FAQ
Can you provide the ChartMill fundamental rating for Five Prime Thera?
ChartMill assigns a fundamental rating of 4 / 10 to FPRX.
What is the valuation status of Five Prime Thera (FPRX) stock?
ChartMill assigns a valuation rating of 1 / 10 to Five Prime Thera (FPRX). This can be considered as Overvalued.
How profitable is Five Prime Thera (FPRX) stock?
Five Prime Thera (FPRX) has a profitability rating of 2 / 10.
What is the earnings growth outlook for Five Prime Thera?
The Earnings per Share (EPS) of Five Prime Thera (FPRX) is expected to grow by 6.99% in the next year.
Is the dividend of Five Prime Thera sustainable?
The dividend rating of Five Prime Thera (FPRX) is 0 / 10 and the dividend payout ratio is 0%.